In a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer, the trial met its primary endpoint of progression-free survival.
Kimberly Leslie, a professor at the University of New Mexico Comprehensive Cancer Center, was awarded a 5-year, $12.9 million grant from NCI. Leslie and her research team, which includes scientists from the Universities of Iowa, Utah, Kansas, Virginia, and California at San Diego, will study all available hormonal regimens to prevent and treat endometrial cancer.
